中文摘要：

表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）已被列为一个与临床相关的、独特的肺癌亚群。虽然EGFR突变的肿瘤患者增加了对酪氨酸激酶抑制剂（TKI）的敏感性,但其耐药仍然是一个主要的临床问题。针对原发和获得性耐药不同的分子机制,包括应用第2代或第3代TKI,以及与EGFR下游信号通路抑制剂的组合用药等多项临床试验已经在启动和计划中。本文综述了近年来EGFR突变的NSCLC耐药机制的新进展和克服耐药的新策略。

英文摘要：

Epidermal growth factor receptor（EGFR）-mutant non-small cell lung cancer（NSCLC） has been defined as a distinct subset of lung cancer in the clinic.Although EGFR-mutant tumours most often display more sensitivity to tyrosine kinase inhibitor（TKI）,clinical resistance to them remains a major problem.Based on the different molecular mechanisms of primary and acquired resistance,multiple clinical trials of the second or third-generation EGFR TKI and drug combinations with inhibitors targeting to EGFR downstream protein have been initiated and are being planned.This review summarizes recent progress in mechanisms and new overcoming strategies on better treatment of drug resistant cancer cells in EGFR-mutant NSCLC.